[Development trend in new therapeutic approaches for anemia]

Area of Science:

• Oncology
• Hematology

Background:

• Anemia is a common complication in cancer patients undergoing treatment.
• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.

Purpose of the Study:

• To summarize current recommendations for managing anemia in cancer patients and MDS.
• To highlight the role of erythropoiesis-stimulating agents (ESAs) and targeted therapies.

Main Methods:

• Review of National Comprehensive Cancer Network (NCCN) guidelines for cancer treatment-related anemia.
• Analysis of treatment strategies for myelodysplastic syndromes (MDS), including specific genetic markers and risk stratification.
• Mention of ongoing clinical trials in Japan for novel therapeutic agents.

Main Results:

• NCCN recommends erythropoietin or darbepoetin alpha for cancer treatment-related anemia, focusing on quality of life improvement.
• Lenalidomide is recommended for MDS with a 5q- anomaly.
• Erythropoietin or darbepoetin alpha are recommended for low-risk MDS without 5q- and low serum erythropoietin levels (<500 mU/ml).

Conclusions:

• Current guidelines provide a framework for managing anemia in cancer and MDS patients.
• ESAs and targeted therapies like lenalidomide offer treatment options based on specific patient characteristics.
• New therapeutic agents are under investigation in clinical trials, potentially expanding future treatment paradigms.